[en] BACKGROUND & AIMS: Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence. METHODS: We evaluated the efficacy of infliximab in preventing postoperative recurrence of CD in 297 patients at 104 sites worldwide from November 2010 through May 2012. All study patients had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) to groups given infliximab (5 mg/kg) or placebo every 8 weeks for 200 weeks. The primary end point was clinical recurrence, defined as a composite outcome consisting of a CD Activity Index score >200 and a >/=70-point increase from baseline, and endoscopic recurrence (Rutgeerts score >/=i2, determined by a central reader) or development of a new or re-draining fistula or abscess, before or at week 76. Endoscopic recurrence was a major secondary end point. RESULTS: A smaller proportion of patients in the infliximab group had a clinical recurrence before or at week 76 compared with the placebo group, but this difference was not statistically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confidence interval: -1.3% to 15.5%; P = .097). A significantly smaller proportion of patients in the infliximab group had endoscopic recurrence compared with the placebo group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95% confidence interval: 18.6% to 40.2%; P < .001). Additionally, a significantly smaller proportion of patients in the infliximab group had endoscopic recurrence based only on Rutgeerts scores >/=i2 (22.4% vs 51.3%; ARR with infliximab, 28.9%; 95% confidence interval: 18.4% to 39.4%; P < .001). Patients previously treated with anti-tumor necrosis factor agents or those with more than 1 resection were at greater risk for clinical recurrence. The safety profile of infliximab was similar to that from previous reports. CONCLUSIONS: Infliximab is not superior to placebo in preventing clinical recurrence after CD-related resection. However, infliximab does reduce endoscopic recurrence. ClinicalTrials.gov ID NCT01190839.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Regueiro, Miguel
Feagan, Brian G.
Zou, Bin
Johanns, Jewel
Blank, Marion A.
Chevrier, Marc
Plevy, Scott
Popp, John
Cornillie, Freddy J.
Lukas, Milan
Danese, Silvio
Gionchetti, Paolo
Hanauer, Stephen B.
Reinisch, Walter
Sandborn, William J.
Sorrentino, Dario
Rutgeerts, Paul
Louis, Edouard ; Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie
J. Cosnes, I. Nion-Larmurier, L. Beaugerie, and et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery Gut 54 2005 237 241
M. Lazarev, T. Ullman, W.H. Schraut, and et al. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center Inflamm Bowel Dis 16 2010 830 835
P. Rutgeerts, K. Geboes, G. Vantrappen, and et al. Predictability of the postoperative course of Crohn's disease Gastroenterology 99 1990 956 963
M. Pascua, C. Su, J.D. Lewis, and et al. Meta-analysis: factors predicting postoperative recurrence with placebo therapy in patients with Crohn's disease Aliment Pharmacol Ther 28 2008 545 556
A.D. Frolkis, D.S. Lipton, K.M. Fierst, and et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies Am J Gastroenterol 109 2014 1739 1748
A.D. Frolkis, J. Dykeman, M.E. Negron, and et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies Gastroenterology 145 2013 996 1006
R. Caprilli, A. Andreoli, L. Capurso, and et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease Aliment Pharmacol Ther 8 1994 35 43
H. Lochs, M. Mayer, W.E. Fleig, and et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI Gastroenterology 118 2000 264 273
R. Caprilli, M. Cottone, F. Tonelli, and et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial Aliment Pharmacol Ther 17 2003 517 523
P. Rutgeerts, M. Hiele, K. Geboes, and et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 108 1995 1617 1621
I. Chermesh, A. Tamir, R. Reshef, and et al. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease Dig Dis Sci 52 2007 385 389
K. Ewe, T. Bottger, H.J. Buhr, and et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group Eur J Gastroenterol Hepatol 11 1999 277 282
G. Hellers, A. Cortot, D. Jewell, and et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group Gastroenterology 116 1999 294 300
S.B. Hanauer, B.I. Korelitz, P. Rugeerts, and et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial Gastroenterology 127 2004 723 729
G.R. D'Haens, S. Vermeire, G. Van Assche, and et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's Disease: a controlled randomized trial Gastroenterology 135 2008 1123 1129
P. Rutgeerts, G. Van Assche, S. Vermeire, and et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial Gastroenterology 128 2005 856 861
D. Sorrentino, G. Terrosu, C. Avellini, and et al. Prevention of postoperative recurrence of Crohn's disease by infliximab Eur J Gastroenterol Hepatol 18 2006 457 459
D. Sorrentino, G. Terrosu, C. Avellini, and et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence Arch Intern Med 167 2007 1804 1807
M. Regueiro, W. Schraut, L. Baidoo, and et al. Infliximab prevents Crohn's disease recurrence after ileal resection Gastroenterology 136 2009 441 450
K. Yoshida, K. Fukunaga, H. Ikeuchi, and et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial Inflamm Bowel Dis 18 2012 1617 1623
K. Papamichael, E. Archavlis, C. Lariou, and et al. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study J Crohns Colitis 6 2012 924 931
E. Savarino, P. Dulbecco, G. Bodini, and et al. Prevention of postoperative recurrence of Crohn's disease by adalimumab: a case series Eur J Gastroenterol Hepatol 24 2012 468 470
M. Aguas, G. Bastida, E. Cerrillo, and et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients World J Gastroenterol 18 2012 4391 4398
A. Armuzzi, C. Felice, A. Papa, and et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study J Crohns Colitis 7 2013 e623 e629
E. Savarino, G. Bodini, P. Dulbecco, and et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial Am J Gastroenterol 108 2013 1731 1742
T. Yamamoto, S. Umegae, and K. Matsumoto Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study Inflamm Bowel Dis 15 2009 1460 1466
D. Sorrentino, G. Terrosu, A. Paviotti, and et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab - a pilot study Dig Dis Sci 57 2012 1341 1348
P. De Cruz, M.A. Kamm, A.L. Hamilton, and et al. Crohn's disease management after intestinal resection: a randomised trial Lancet 385 2015 1406 1417
W.R. Best, J.M. Becktel, J.W. Singleton, and et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study Gastroenterology 70 1976 439 444
G.E. Reese, T. Nanidis, Borysiewicz, and et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies Int J Colorectal Dis 23 2008 1213 1221
V. Binder, C. Hendriksen, and S. Kreiner Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen Gut 26 1985 146 150
L.R. Sutherland, S. Ramcharan, H. Bryant, and et al. Effect of cigarette smoking on recurrence of Crohn's disease Gastroenterology 98 Pt 1 1990 1123 1128
R. Caprilli, G. Corrao, G. Taddei, and et al. Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) Dis Colon Rectum 39 1996 335 341
C. Simillis, T. Yamamoto, G.E. Reese, and et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease Am J Gastroenterol 103 2008 196 205
R.S. McLeod, B.G. Wolff, S. Ross, and et al. Investigators of the CAST Trial. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial Dis Colon Rectum 52 2009 919 927
Remicade [package insert] 2015 Janssen Biotech, Inc Horsham, PA
K. Reich, G. Wozel, H. Zheng, and et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2) Br J Dermatol 168 2013 1325 1334
S.B. Hanauer, C.L. Wagner, M. Bala, and et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 2004 542 553
J.-F. Colombel, W.J. Sandborn, W. Reinisch, and et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
S.C. Ng, and M.A. Kamm Management of postoperative Crohn's disease Am J Gastroenterol 103 2008 1029 1035
P. Rutgeerts Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions Aliment Pharmacol Ther 24 Suppl 3 2006 29 32
M. Cottone, A. Orlando, and I. Modesto Postoperative maintenance therapy for inflammatory bowel disease Curr Opin Gastroenterol 22 2006 377 381
J.M. Swoger, and M. Regueiro Postoperative Crohn's disease: how can we prevent it? Expert Rev Clin Immunol 6 2010 501 504
T.D. Walters, A.H. Steinhart, C.N. Bernstein, and et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence Inflamm Bowel Dis 17 2011 1547 1556
D.L. Nguyen, P. Solaimani, E.T. Nguyen, and et al. Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: a meta-analysis Eur J Gastroenterol Hepatol 26 2014 1152 1159
L. Peyrin-Biroulet, W. Walter Reinisch, J.-F. Colombel, and et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial Gut 63 2014 88 95
M. Regueiro, K.E. Kip, W. Schraut, and et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection Inflamm Bowel Dis 17 2011 118 126
M. Regueiro, K.E. Kip, L. Baidoo, and et al. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence Clin Gastroenterol Hepatol 12 2014 1494 1502
J.-F. Colombel, P.J. Rutgeerts, W.J. Sandborn, and et al. Adalimumab induces deep remission in patients with Crohn's disease Clin Gastroenterol Hepatol 12 2014 414 422
J.-F. Colombel, W. Reinisch, G.J. Mantzaris, and et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis Aliment Pharmacol Ther 41 2015 734 746